Autocrine regulation of cell proliferation by estrogen receptor-alpha in estrogen receptor-alpha-positive breast cancer cell lines
© Tan et al; licensee BioMed Central Ltd. 2009
Received: 19 September 2008
Accepted: 26 January 2009
Published: 26 January 2009
Estrogen receptor-α (ERα) is essential for mammary gland development and is a major oncogene in breast cancer. Since ERα is not colocalized with the cell proliferation marker Ki-67 in the normal mammary glands and the majority of primary breast tumors, it is generally believed that paracrine regulation is involved in ERα mediated cell proliferation. In the paracrine model, ERα-positive cells don't proliferate but will release some paracrine growth factors to stimulate the neighboring cells to proliferate. In a subpopulation of cancer cells in some primary breast tumors, however, ERα does colocalize with the cell proliferation marker Ki-67, suggesting an autocrine regulation by ERα in some primary breast tumors.
Colocalization of ERα with Ki-67 in ERα-positive breast cancer cell lines (MCF-7, T47D, and ZR75-1) was evaluated by immunofluorescent staining. Cell cycle phase dependent expression of ERα was determined by co-immunofluorescent staining of ERα and the major cyclins (D, E, A, B), and by flow cytometry analysis of ERαhigh cells. To further confirm the autocrine action of ERα, MCF-7 cells were growth arrested by ICI182780 treatment, followed by treatment with EGFR inhibitor, before estrogen stimulation and analyses for colocalization of Ki-67 and ERα and cell cycle progression.
Colocalization of ERα with Ki-67 was present in all three ERα-positive breast cancer cell lines. Unlike that in the normal mammary glands and the majority of primary breast tumors, ERα is highly expressed throughout the cell cycle in MCF-7 cells. Without E2 stimulation, MCF-7 cells released from ICI182780 treatment remain at G1 phase. E2 stimulation of ICI182780 treated cells, however, promotes the expression and colocalization of ERα and Ki-67 as well as the cell cycle progressing through the S and G2/M phases. Inhibition of EGFR signaling does not inhibit the autocrine action of ERα.
Our data indicate that ERα can mediate estrogen-induced cell proliferation in an autocrine mode in ERα-positive breast cancer cell lines. All of the three ERα-positive cell lines used in our study showed colocalization of ERα and Ki-67, indicating that these cell lines might be originated from primary tumor cells with autocrine regulation.
The ovarian-derived steroid hormone estrogen is one of the main regulators of mammary epithelial cell proliferation and differentiation. While estrogen is required for normal mammary gland development, cumulative exposure to estrogen during a woman's lifetime is a high risk factor for breast malignancy. The action of estrogen is exerted by binding and activating the estrogen receptors, ERα and ERβ. Studies on the expression patterns of estrogen receptors and gene knock-out mouse models indicate that ERα is the primary estrogen receptor for mammary epithelial cell proliferation and differentiation. While ERα is expressed exclusively in the epithelial cells, ERβ is expressed in both epithelial and stromal cells but the expression of ERβ in the epithelial cells is very weak [1–4]. In ERβ knock-out mice, the mammary glands can still form the bronchoalveolar structure and lactate normally [5, 6]. In ERα knock-out mice, however, the mammary gland remains at rudimentary duct stage without further development [7–9]. While the role of ERβ in breast cancer is less understood, ERα is one of the most known oncogenes in breast cancer [10–12]. Abnormal expression of ERα is found in about 70–80% of human breast cancers, and about 50% of ERα-positive breast cancer patients respond to anti-estrogen therapy [10, 13]. When overexpressed in the mammary gland epithelial cells of transgenic mice, ERα leads to mammary malignancy [14, 15].
Despite the significant role of ERα in mediating estrogen-induced cell proliferation in normal mammary development and breast cancer, the mechanism is still not fully understood. In the normal mammary gland, ERα expression is found only in a subpopulation of the mammary epithelial cells and the percentage of ERα-positive cells is affected by the physiologic conditions. Unlike most other cellular receptors, ERα expression is not found in proliferating mammary epithelial cells [1–3, 16–18]. This observation leads to the prevailing concept that ERα mediates cell proliferation in a paracrine manner [1, 19]. In this paracrine model, ERα-positive cells don't proliferate; the ERα-positive cells, however, when stimulated by estrogen, will produce and release paracrine growth factors, which in turn stimulate the neighboring cells to proliferate [1, 9]. The EGF family member amphiregulin could be one of those important paracrine growth factors involved in ERα-mediated mammary gland epithelial cell proliferation . It is not clear why ERα-positive cells cannot proliferate, or why ERα does not stimulate cell proliferation in an autocrine mode or in both autocrine and paracrine modes. A recent study by Cheng et al. challenged the paradigm that ERα cannot mediate ERα-positive cell proliferation . The authors proposed that ERα is degraded early in the cell cycle, which accounts for the dissociation of the ERα-staining and cell proliferation marker.
In contrast to the mechanism in normal mammary tissues, ERα might mediate cancer cell proliferation via paracrine and/or autocrine modes in primary breast cancers. In ERα-positive primary breast cancers, the percentage of ERα-staining cells varies from 10% to 50% or higher [1, 3, 21, 22]. Most of the ERα-staining cells are not stained with Ki-67 in these ERα-positive primary breast tumors [1, 3, 23, 24]. In some primary breast tumors, however, ERα does colocalize with the cell proliferation marker Ki-67 in a sub-population of tumor cells; the percentage of ERα and Ki-67 duel-staining cells varies among different patients, from 0% to ~5% of total cells [1, 3]. The co-staining of ERα and Ki-67 suggests that ERα-positive cells in these primary breast tumors might be capable of proliferating, i.e., ERα might be able to mediate cell proliferation via autocrine fashion in these primary breast tumor cells.
Using breast cancer cell line models, ERα has been shown to have non-genomic effect in addition to the traditional genomic action . In its genomic action as a transcriptional factor, ERα activation in MCF-7 cells can induce the expression of cyclin D and myc to promote cell cycle progression [26–29]. When stimulated by estrogen, the effect on cell proliferation in MCF-7 cells is usually not obvious until 5–7 days after the stimulation [30–32]. It is not clear why the impact is delayed for such long time and that raises the question whether the activation of ERα alone is sufficient to drive cell cycle progression through all the phases for mitosis. For the non-genomic action of ERα, cell signaling initiated from the cell surface can activate multiple pathways such as the ERK and AKT pathways [33–35]. Using the EGFR inhibitor, Levine and colleagues demonstrated that EGFR is required for the cell surface ERα-activated signaling transduction . Marks and colleagues demonstrated that inhibition of the MAPK and PI3K-AKT pathways can prevent estrogen-induced mitogenesis in MCF-7 cells . Considering all of the information derived from different perspectives, it is very likely that MCF-7 cells and some other ERα-positive breast cancer cell lines might be regulated by ERα via the autocrine as well as the paracrine modes. In this study, we demonstrated that ERα is colocalized with Ki-67 in MCF-7, T47D, and ZR75-1 cells, the ERα-positive breast cancer cell lines used in our study. Using MCF-7 cell line, we demonstrated that ERα is present in all the phases of cell cycle and activation of ERα in G1 phase promotes cell cycle progression through mitogenesis, supporting the autocrine mode of regulation. Finally, we demonstrated that EGFR activation is not required for the autocrine regulation of cell proliferation by ERα.
Chemicals and antibodies
Antibodies for ERα (F10), Ki-67 (H-300), cyclin A (C-19), Cyclin B (H-20), cyclin D1 (H-295), cyclin E (C-19) were obtained from Santa Cruz (Santa Cruz, CA). Blocking peptides for ERα (F10), cyclin A (C-19), cyclin E (C-19) were obtained from Santa Cruz (Santa Cruz, CA). Antibodies for ERK1/2 (137F5), phospho-ERK1/2 (E10), AKT, phospho-AKT/Ser473, and EGFR were obtained from Cell Signaling Technology (Danvers, MA). Secondary antibody conjugated with Alexa Fluor 488 (Molecular Probes, Inc, Eugene, OR) was used for green fluorescent staining, secondary antibody conjugated with Rhodamine Red-X (Jackson ImmunoResearch, West Grove, PA) was used for red fluorescent staining. Heat inactivated FBS and Charcoal-Dextrin stripped FBS (CD-FBS) were obtained from Omega (Tarzana, CA). Estrogen was obtained from Sigma (St. Louis, MO). ICI182780 was obtained from TOCRIS (Ellisville, MO). Gefitinib was obtained from LC Laboratories (Woburn, MA). EGF was obtained from Invitrogen (Carlsbad, CA).
Cell culture and treatments
DMEM/F12 medium (MediaTech Inc, Herndon, VA) containing 10% heat inactivated FBS and 5 μg/ml insulin was used for routine maintenance of the three ERα-positive breast cancer cell lines, MCF-7, T47D, and ZR75-1 (ATCC). For experimental assays, phenol-red free DMEM/F12 (MediaTech Inc, Herndon, VA) containing 5% CD-FBS was used unless otherwise specified. To arrest cells in G1 phase by ICI182780, cells were seeded in culture dishes for 1–2 days to let the cells reach about 30–40% confluency before replacement with medium containing ICI182780. To evaluate the effect of estrogen stimulation, cells were stimulated by adding E2 either after removal of ICI182780 or in the presence of ICI182780. For estrogen stimulation after removal of ICI182780, cells treated with ICI182780 were washed briefly two times with serum-free phenol red-free DMEM/F12 to remove ICI182780, followed by replacement with medium containing 5 nM estrogen but without ICI182780. The control cells were replaced with medium containing vehicle only. For estrogen stimulation in the presence of ICI182780, cells were treated with 10 nM ICI182780 for various times before adding ten fold of E2 (100 nM) to the cells without removing ICI182780. ICI182780 stock solution was made at 10 mM in DMSO, then serially diluted in DMSO to 10 μM before diluted in culture medium. Estrogen stock solution was made at 10 mM in ethanol, then serially diluted in ethanol to 10 μM before diluted in culture medium. To inhibit the EGFR activation, cells were treated with Gefitinib for 2 hr first; without removing Gefitinib, estrogen or EGF was then added to the cells for stimulation. Gefitinib stock was made in DMSO at 1–50 mM, the stock was diluted in culture medium to make the final concentrations at 1–50 μM.
Cells grown on glass coverslips were briefly washed with ice-cold Dulbecco's PBS and fixed with cold 4% paraformaldehyde containing 0.01% Triton X-100 for 25 min on ice. After washing once briefly with PBS-T (Dulbelcco's PBS containing 0.01% Triton X-100), the cells were treated with 0.05% Triton x-100 in PBS for 10 min for permeabilization. The cells were washed once briefly with PBS-T, followed by blocking in PBS-T containing 5% normal serum and 50 mM NH4Cl for 30 min at room temperature. The cells were then incubated with primary antibodies diluted in PBS-T containing 1% normal serum. Anti-ERα antibody was diluted at 1:50, anti-Ki-67 at 1:100, anti-cyclin D at 1:150, anti-cyclin E at 1:100, anti-cyclin A at 1:100, and anti-cyclin B at 1:100. For the antibodies with blocking peptides available, the antibodies (ERα, cyclin A, cyclin E) were evaluated for its binding specificity by incubation with 5 fold of blocking peptides before applying to cells for primary antibody incubation. After overnight incubation at 4°C, the cells were washed four times with PBS-T, 7 min each time. Then the cells were incubated for 1 hr at room temperature with fluorescent dye-conjugated secondary antibodies (1:200) in PBS-T containing 1% normal serum. The cells were washed 4 times with PBS-T, 7 min each time before mounted on slides with VectoShield with DAPI (Vector Laboratories, Burlingame, CA). Immunofluorescent staining(s) was observed under Olympus BX50 Fluorescence Microscope with Optronics MagnaFire digital camera (Microscope Image Center, UVM).
Flow cytometry analysis
For analysis of cell cycle distribution, cells were harvested by trypsinization, pelleted by centrifugation, and washed once with Dulbecco's PBS. While vortexing cells, ice-cold 70–75% ethanol was added drop wise to resuspend the cells. The cells were fixed in 70% ethanol for at least 1 hr at 4°C before staining or stored at -20°C freezer. Before staining, 1–3 millions of cells were pelleted, washed once with PBS, followed by resuspension in 1 ml PBS containing 20 μg/ml PI (propidium iodide), 150 μg/ml RNaseA, 10 mM EDTA, and 0.1% Triton X-100. Incubation was carried in the dark at 37°C for 15–30 min. For the analysis of cell cycle distribution of ERα-staining cells, cells were harvested by trypsinization and the cell number counted. The cells were pelleted by centrifugation (2000 rpm, 5 min, 4°C). After resuspension with culture medium, 3 million of cells were transferred into Ependorff tube and pelleted by centrifugation (500 × g, 4°C, 2 min). The cell pellet was resuspended in 1 ml PBS-T containing 1% paraformaldehyde and cells were fixed on ice for 10 min. The cells were pelleted by brief centrifugation, resuspended in PBS containing 0.05% Triton-X100 for permeabilization at room temperature for 5 min. After brief washing, cells were incubated with 5% normal serum in PBS-T (30 min, room temperature) for blocking. Cells were pelleted and resuspended in PBS-T containing anti-ERα (F10, 1:100 dilution) and 0.5% BSA, followed by incubation at 4°C for overnight. The cells were washed 4 times with PBS-T, 7 min each, by centrifugation and resuspension, followed by incubation with the secondary antibody anti-mouse Alexa Fluor 488 (1:300) at room temperature for 40 min. After washing with PBS-T for 4 times, 7 min each, the cells were incubated with 0.5 ml PI-RNaseA solution for 30 min at 37°C. Flow cytometry analysis was performed using the Coulter Epics XL-MCL (VCC core facility, UVM). About 20,000 cells were analyzed for each sample.
Protein analysis by immuno-blotting
Cells at 70–80% confluence were washed briefly twice with ice-cold D-PBS before scraping on ice with lysis buffer (20 mM Tris-HCl, pH 7.5; 150 mM NaCl; 2.5 mM sodium pyrophosphate; 1 mM sodium β-glycerophosphate; 5 mM NaF, 1 mM Na3VO4, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, and 1 tablet of protease inhibitor mixture (Roche Molecular Biochemicals, Indianapolis, IN) per 40 ml of lysis buffer). Cellular debris was removed by centrifugation (14,000 × g for 15 min at 4°C). For SDS-PAGE, total cell lysate containing ~30 μg proteins were separated on 12% SDS-PAGE gel and transferred onto PVDF membranes (Millipore, Bedford, MA). Immunoblotting was carried out followed standard procedures [37, 38].
Colocalization of ERα and Ki67 in ERα-positive breast cancer cell lines
Deregulated expression of ERα in all phases of cell cycle
E2 stimulation of ICI182780 treated cells induces expression of ERα and Ki-67
E2 stimulation releases cell cycle arrest by ICI182780 to promote cell cycle progression
EGFR signaling is not required for the autocrine regulation of cell proliferation by ERα
ERα is the primary estrogen receptor mediating the effects of estrogen in normal mammary epithelial cells [1–3, 5–9, 43]. In breast cancer, abnormal expression of ERα is found in about 70% of primary tumors [10, 13]. Despite the significant role of ERα, the mechanism of how ERα mediates cell proliferation is not fully understood. The dissociation of ERα with cell proliferation markers such as Ki-67 in the normal mammary gland leads to the paracrine model of ERα-mediated cell proliferation. While colocalization of ERα and Ki-67 is rare in most primary breast cancers, there do exist some cancer cells in some primary breast tumors showing colocalization of ERα and Ki-67 suggesting the possibility of autocrine regulation. In this paper using the ERα-positive breast cancer lines, we presented data showing that most Ki-67 staining cells expressed high levels of ERα and that cells with high levels of ERα are distributed across different phases of cell cycle. We further demonstrated that activation of ERα in ICI182780 arrested cells can induce the expression and colocalization of high levels of ERα and Ki-67, and more importantly, the progressing of cell cycles from G1 phase to the G2/M phases. Collectively, our data support the hypothesis that ERα can mediate cell proliferation in an autocrine mode in these ERα-positive breast cancer cell lines.
Whether ERα mediates cell proliferation by autocrine and/or paracrine regulation is related to whether ERα-positive cells can proliferate or not. Inferred from the paracrine model is that ERα-positive cells are a separate sub-population of cells that don't proliferate, or even further that ERα-positive cells cannot proliferate because ERα inhibits the proliferation of ERα-positive cells [1, 3, 44, 45]. Although ERα is known to promote cell proliferation in ERα-positive breast cancer cell lines such as MCF-7, exogenous overexpression of ERα in some cell lines such as MDA-MB-231 and MCF-10A does inhibit cell proliferation [46–50]. The mechanism of how ERα mediates cell proliferation may have clinical implication for breast cancer etiology and therapy. Malignant transformation is a multistep process that involves different combination of genes at different stage of malignancy . Distinct sets of ERα-target genes might be involved for the autocrine versus paracrine regulation and it will be interesting to examine whether the resistance to endocrine-related therapy is correlated with the mode of ERα action.
All the three ERα-positive cell lines used in our study showed colocalization of ERα and Ki-67. Since the number of established ERα-positive breast cancer cell lines is much less than expected from the expression frequency of ERα in primary breast tumors, we speculated that ERα-positive cell lines could only be established from cancer cells with autocrine regulation in the primary tumors [13, 52]. In that case, what is known about the breast cancer from the studies using the ERα-positive breast cancer cell lines may not apply to all the ERα-positive primary breast tumors. It needs to point out that although our data support the autocrine mode of ERα action, it remains to determine whether both autocrine and paracrine modes of action by ERα are involved in these ERα-positive breast cancer cell lines. ERα is expressed in both the nucleus and cell surface in MCF-7 cells [53, 54]. Based on the levels of membrane ERα, MCF-7 cells can be separated into two sub-populations, mERαhigh and mERαlow [55, 56]. The levels of nuclear ERα also showed heterogeneity in MCF-7 cells. It is not clear whether the heterogeneity of nuclear ERα levels is caused by the differential expression of ERα during cell cycle progression or by the heterogeneous sub-populations of cells. As demonstrated in ICI182780 treated cells, even extremely low or basal level of ERα can mediate some of the cellular response to estrogen. To determine whether paracrine regulation is involved or not, a subline of MCF-7 with the ERα being completely shut off, i.e., eliminating the low basal level of ERα, will be needed to test their proliferation in response to estrogen when mixed with normal MCF-7 cells.
Together with the systemic hormones, growth factors are involved in mammary cell proliferation. EGFR signaling is essential for ERα-mediated cell proliferation in the normal mammary glands . In MCF-7 cells, EGFR is involved in the non-genomic action of ERα and blocking of some EGFR activated pathways could inhibit ERα-mediated cell proliferation [33–36]. Our data, however, indicate that EGFR signaling is not required for the autocrine regulation of cell proliferation by ERα.
ERα can mediate estrogen-induced cell proliferation in an autocrine mode in ERα-positive breast cancer cell lines. All of the three ERα-positive cell lines used in our study showed colocalization of ERα and Ki-67, indicating that these cell lines might be originated from primary tumor cells with autocrine regulation. Considering that the number of established ERα-positive breast cancer cell lines is much less than expected from the percentage of ERα-positive primary breast tumors, we speculated that ERα-positive cell lines could only be established from cancer cells with autocrine regulation in the primary tumors. In that case, what is learnt about the breast cancer from the studies using the ERα-positive breast cancer cell lines may not apply to all the ERα-positive primary breast tumors.
This study is supported by the VCC/LCCRO (Vermont Cancer Center/Lake Champlain Cancer Research Organization) funds to ZZ Pan.
- Clarke RB, Howell A, Potten CS, Anderson E: Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Res. 1997, 57: 4987-4991.PubMedGoogle Scholar
- Russo J, Ao X, Grill C, Russo IH: Pattern of distribution of cells positive for estrogen receptor alpha and progesterone receptor in relation to proliferating cells in the mammary gland. Breast Cancer Res Treat. 1999, 53: 217-227. 10.1023/A:1006186719322.View ArticlePubMedGoogle Scholar
- Shoker BS, Jarvis C, Clarke RB, Anderson E, Hewlett J, Davies MP, Sibson DR, Sloane JP: Estrogen receptor-positive proliferating cells in the normal and precancerous breast. Am J Pathol. 1999, 155: 1811-1815.View ArticlePubMedPubMed CentralGoogle Scholar
- Speirs V, Skliris GP, Burdall SE, Carder PJ: Distinct expression patterns of ER alpha and ER beta in normal human mammary gland. J Clin Pathol. 2002, 55: 371-374.View ArticlePubMedPubMed CentralGoogle Scholar
- Krege JH, Hodgin JB, Couse JF, Enmark E, Warner M, Mahler JF, Sar M, Korach KS, Gustafsson JA, Smithies O: Generation and reproductive phenotypes of mice lacking estrogen receptor beta. Proc Natl Acad Sci USA. 1998, 95: 15677-15682. 10.1073/pnas.95.26.15677.View ArticlePubMedPubMed CentralGoogle Scholar
- Forster C, Makela S, Warri A, Kietz S, Becker D, Hultenby K, Warner M, Gustafsson JA: Involvement of estrogen receptor beta in terminal differentiation of mammary gland epithelium. Proc Natl Acad Sci USA. 2002, 99: 15578-15583. 10.1073/pnas.192561299.View ArticlePubMedPubMed CentralGoogle Scholar
- Bocchinfuso WP, Korach KS: Mammary gland development and tumorigenesis in estrogen receptor knockout mice. J Mammary Gland Biol Neoplasia. 1997, 2: 323-334. 10.1023/A:1026339111278.View ArticlePubMedGoogle Scholar
- Herynk MH, Fuqua SA: Estrogen receptor mutations in human disease. Endocr Rev. 2004, 25: 869-898. 10.1210/er.2003-0010.View ArticlePubMedGoogle Scholar
- Mallepell S, Krust A, Chambon P, Brisken C: Paracrine signaling through the epithelial estrogen receptor alpha is required for proliferation and morphogenesis in the mammary gland. Proc Natl Acad Sci USA. 2006, 103: 2196-2201. 10.1073/pnas.0510974103.View ArticlePubMedPubMed CentralGoogle Scholar
- Regan MM, Viale G, Mastropasqua MG, Maiorano E, Golouh R, Carbone A, Brown B, Suurkula M, Langman G, Mazzucchelli L, et al: Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays. J Natl Cancer Inst. 2006, 98: 1571-1581.View ArticlePubMedGoogle Scholar
- Khan SA, Rogers MA, Khurana KK, Meguid MM, Numann PJ: Estrogen receptor expression in benign breast epithelium and breast cancer risk. J Natl Cancer Inst. 1998, 90: 37-42. 10.1093/jnci/90.1.37.View ArticlePubMedGoogle Scholar
- Khan SA, Rogers MA, Obando JA, Tamsen A: Estrogen receptor expression of benign breast epithelium and its association with breast cancer. Cancer Res. 1994, 54: 993-997.PubMedGoogle Scholar
- Kuukasjarvi T, Kononen J, Helin H, Holli K, Isola J: Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. J Clin Oncol. 1996, 14: 2584-2589.PubMedGoogle Scholar
- Frech MS, Halama ED, Tilli MT, Singh B, Gunther EJ, Chodosh LA, Flaws JA, Furth PA: Deregulated estrogen receptor alpha expression in mammary epithelial cells of transgenic mice results in the development of ductal carcinoma in situ. Cancer Res. 2005, 65: 681-685.PubMedGoogle Scholar
- Tilli MT, Frech MS, Steed ME, Hruska KS, Johnson MD, Flaws JA, Furth PA: Introduction of estrogen receptor-alpha into the tTA/TAg conditional mouse model precipitates the development of estrogen-responsive mammary adenocarcinoma. Am J Pathol. 2003, 163: 1713-1719.View ArticlePubMedPubMed CentralGoogle Scholar
- Cheng G, Li Y, Omoto Y, Wang Y, Berg T, Nord M, Vihko P, Warner M, Piao YS, Gustafsson JA: Differential regulation of estrogen receptor (ER)alpha and ERbeta in primate mammary gland. J Clin Endocrinol Metab. 2005, 90: 435-444. 10.1210/jc.2004-0861.View ArticlePubMedGoogle Scholar
- Cheng G, Weihua Z, Warner M, Gustafsson JA: Estrogen receptors ER alpha and ER beta in proliferation in the rodent mammary gland. Proc Natl Acad Sci USA. 2004, 101: 3739-3746. 10.1073/pnas.0307864100.View ArticlePubMedPubMed CentralGoogle Scholar
- Saji S, Jensen EV, Nilsson S, Rylander T, Warner M, Gustafsson JA: Estrogen receptors alpha and beta in the rodent mammary gland. Proc Natl Acad Sci USA. 2000, 97: 337-342. 10.1073/pnas.97.1.337.View ArticlePubMedPubMed CentralGoogle Scholar
- Clarke R: Complementary yet distinct roles for oestrogen receptor-α and oestrogen receptor-β in mouse mammary epithelial proliferation. Breast Cancer Res. 2004, 6: 135-136. 10.1186/bcr795.View ArticlePubMedPubMed CentralGoogle Scholar
- Ciarloni L, Mallepell S, Brisken C: Amphiregulin is an essential mediator of estrogen receptor alpha function in mammary gland development. Proc Natl Acad Sci USA. 2007, 104: 5455-5460. 10.1073/pnas.0611647104.View ArticlePubMedPubMed CentralGoogle Scholar
- Shaaban AM, O'Neill PA, Davies MP, Sibson R, West CR, Smith PH, Foster CS: Declining estrogen receptor-beta expression defines malignant progression of human breast neoplasia. Am J Surg Pathol. 2003, 27: 1502-1512. 10.1097/00000478-200302000-00021.View ArticlePubMedGoogle Scholar
- Shaaban AM, Sloane JP, West CR, Foster CS: Breast cancer risk in usual ductal hyperplasia is defined by estrogen receptor-alpha and Ki-67 expression. Am J Pathol. 2002, 160: 597-604.View ArticlePubMedPubMed CentralGoogle Scholar
- Jarzabek K, Koda M, Kozlowski L, Mittre H, Sulkowski S, Kottler ML, Wolczynski S: Distinct mRNA, protein expression patterns and distribution of oestrogen receptors alpha and beta in human primary breast cancer: correlation with proliferation marker Ki-67 and clinicopathological factors. Eur J Cancer. 2005, 41: 2924-2934. 10.1016/j.ejca.2005.09.010.View ArticlePubMedGoogle Scholar
- Jensen EV, Cheng G, Palmieri C, Saji S, Makela S, Van Noorden S, Wahlstrom T, Warner M, Coombes RC, Gustafsson JA: Estrogen receptors and proliferation markers in primary and recurrent breast cancer. Proc Natl Acad Sci USA. 2001, 98: 15197-15202. 10.1073/pnas.211556298.View ArticlePubMedPubMed CentralGoogle Scholar
- Pedram A, Razandi M, Aitkenhead M, Hughes CC, Levin ER: Integration of the non-genomic and genomic actions of estrogen. Membrane-initiated signaling by steroid to transcription and cell biology. J Biol Chem. 2002, 277: 50768-50775. 10.1074/jbc.M210106200.View ArticlePubMedGoogle Scholar
- Doisneau-Sixou SF, Sergio CM, Carroll JS, Hui R, Musgrove EA, Sutherland RL: Estrogen and antiestrogen regulation of cell cycle progression in breast cancer cells. Endocr Relat Cancer. 2003, 10: 179-186. 10.1677/erc.0.0100179.View ArticlePubMedGoogle Scholar
- Musgrove EA, Sutherland RL: Cell cycle control by steroid hormones. Semin Cancer Biol. 1994, 5: 381-389.PubMedGoogle Scholar
- Prall OW, Rogan EM, Musgrove EA, Watts CK, Sutherland RL: c-Myc or cyclin D1 mimics estrogen effects on cyclin E-Cdk2 activation and cell cycle reentry. Mol Cell Biol. 1998, 18: 4499-4508.View ArticlePubMedPubMed CentralGoogle Scholar
- Sutherland RL, Prall OW, Watts CK, Musgrove EA: Estrogen and progestin regulation of cell cycle progression. J Mammary Gland Biol Neoplasia. 1998, 3: 63-72. 10.1023/A:1018774302092.View ArticlePubMedGoogle Scholar
- Aakvaag A, Utaaker E, Thorsen T, Lea OA, Lahooti H: Growth control of human mammary cancer cells (MCF-7 cells) in culture: effect of estradiol and growth factors in serum-containing medium. Cancer Res. 1990, 50: 7806-7810.PubMedGoogle Scholar
- Soto AM, Sonnenschein C: Mechanism of estrogen action on cellular proliferation: evidence for indirect and negative control on cloned breast tumor cells. Biochem Biophys Res Commun. 1984, 122: 1097-1103. 10.1016/0006-291X(84)91204-X.View ArticlePubMedGoogle Scholar
- Soto AM, Sonnenschein C: The role of estrogens on the proliferation of human breast tumor cells (MCF-7). J Steroid Biochem. 1985, 23: 87-94. 10.1016/0022-4731(85)90265-1.View ArticlePubMedGoogle Scholar
- Pedram A, Razandi M, Levin ER: Nature of functional estrogen receptors at the plasma membrane. Mol Endocrinol. 2006, 20: 1996-2009. 10.1210/me.2005-0525.View ArticlePubMedGoogle Scholar
- Razandi M, Pedram A, Levin ER: Plasma membrane estrogen receptors signal to antiapoptosis in breast cancer. Mol Endocrinol. 2000, 14: 1434-1447. 10.1210/me.14.9.1434.View ArticlePubMedGoogle Scholar
- Razandi M, Pedram A, Park ST, Levin ER: Proximal events in signaling by plasma membrane estrogen receptors. J Biol Chem. 2003, 278: 2701-2712. 10.1074/jbc.M205692200.View ArticlePubMedGoogle Scholar
- Lobenhofer EK, Huper G, Iglehart JD, Marks JR: Inhibition of mitogen-activated protein kinase and phosphatidylinositol 3-kinase activity in MCF-7 cells prevents estrogen-induced mitogenesis. Cell Growth Differ. 2000, 11: 99-110.PubMedGoogle Scholar
- Pan ZZ, Bruening W, Giasson BI, Lee VM, Godwin AK: Gamma-synuclein promotes cancer cell survival and inhibits stress- and chemotherapy drug-induced apoptosis by modulating MAPK pathways. J Biol Chem. 2002, 277: 35050-35060. 10.1074/jbc.M201650200.View ArticlePubMedGoogle Scholar
- Pan ZZ, Bruening W, Godwin AK: Involvement of RHO GTPases and ERK in synuclein-gamma enhanced cancer cell motility. Int J Oncol. 2006, 29: 1201-1205.PubMedGoogle Scholar
- Scholzen T, Gerdes J: The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000, 182: 311-322. 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9.View ArticlePubMedGoogle Scholar
- Johnson DG, Walker CL: Cyclins and cell cycle checkpoints. Annu Rev Pharmacol Toxicol. 1999, 39: 295-312. 10.1146/annurev.pharmtox.39.1.295.View ArticlePubMedGoogle Scholar
- Caldon CE, Daly RJ, Sutherland RL, Musgrove EA: Cell cycle control in breast cancer cells. J Cell Biochem. 2006, 97: 261-274. 10.1002/jcb.20690.View ArticlePubMedGoogle Scholar
- Yam CH, Fung TK, Poon RY: Cyclin A in cell cycle control and cancer. Cell Mol Life Sci. 2002, 59: 1317-1326. 10.1007/s00018-002-8510-y.View ArticlePubMedGoogle Scholar
- Roger P, Sahla ME, Makela S, Gustafsson JA, Baldet P, Rochefort H: Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors. Cancer Res. 2001, 61: 2537-2541.PubMedGoogle Scholar
- Ewan KB, Oketch-Rabah HA, Ravani SA, Shyamala G, Moses HL, Barcellos-Hoff MH: Proliferation of estrogen receptor-alpha-positive mammary epithelial cells is restrained by transforming growth factor-beta1 in adult mice. Am J Pathol. 2005, 167: 409-417.View ArticlePubMedPubMed CentralGoogle Scholar
- Grimm SL, Rosen JM: Stop! In the name of transforming growth factor-beta: keeping estrogen receptor-alpha-positive mammary epithelial cells from proliferating. Breast Cancer Res. 2006, 8: 106-10.1186/bcr1520.View ArticlePubMedPubMed CentralGoogle Scholar
- Abukhdeir AM, Blair BG, Brenner K, Karakas B, Konishi H, Lim J, Sahasranaman V, Huang Y, Keen J, Davidson N, et al: Physiologic estrogen receptor alpha signaling in non-tumorigenic human mammary epithelial cells. Breast Cancer Res Treat. 2006, 99: 23-33. 10.1007/s10549-006-9177-0.View ArticlePubMedGoogle Scholar
- Jiang SY, Jordan VC: Growth regulation of estrogen receptor-negative breast cancer cells transfected with complementary DNAs for estrogen receptor. J Natl Cancer Inst. 1992, 84: 580-591. 10.1093/jnci/84.8.580.View ArticlePubMedGoogle Scholar
- Barron-Gonzalez A, Castro Romero I: Re-expression of estrogen receptor alpha using a tetracycline-regulated gene expression system induced estrogen-mediated growth inhibition of the MDA-MB-231 breast cancer cell line. Biochem Cell Biol. 2004, 82: 335-342. 10.1139/o03-083.View ArticlePubMedGoogle Scholar
- Wang W, Smith R, Burghardt R, Safe SH: 17 beta-Estradiol-mediated growth inhibition of MDA-MB-468 cells stably transfected with the estrogen receptor: cell cycle effects. Mol Cell Endocrinol. 1997, 133: 49-62. 10.1016/S0303-7207(97)00142-1.View ArticlePubMedGoogle Scholar
- Briand P, Lundholt BK, Skouv J, Lykkesfeldt AE: Growth response of breast epithelial cells to estrogen is influenced by EGF. Mol Cell Endocrinol. 1999, 153: 1-9. 10.1016/S0303-7207(99)00099-4.View ArticlePubMedGoogle Scholar
- Pan ZZ, Godwin AK: ONCOGENES. Encyclopedia of Molecular Cell Biology and Molecular Medicine. Edited by: Meyers RA. 2005, Wiley-VCH Verlag GmbH & Co. KgaA, Weinheim, 9: 435-495. 2Google Scholar
- Lacroix M, Leclercq G: Relevance of breast cancer cell lines as models for breast tumours: an update. Breast Cancer Res Treat. 2004, 83: 249-289. 10.1023/B:BREA.0000014042.54925.cc.View ArticlePubMedGoogle Scholar
- Razandi M, Pedram A, Greene GL, Levin ER: Cell membrane and nuclear estrogen receptors (ERs) originate from a single transcript: studies of ERalpha and ERbeta expressed in Chinese hamster ovary cells. Mol Endocrinol. 1999, 13: 307-319. 10.1210/me.13.2.307.PubMedGoogle Scholar
- Razandi M, Pedram A, Merchenthaler I, Greene GL, Levin ER: Plasma membrane estrogen receptors exist and functions as dimers. Mol Endocrinol. 2004, 18: 2854-2865. 10.1210/me.2004-0115.View ArticlePubMedGoogle Scholar
- Zivadinovic D, Gametchu B, Watson CS: Membrane estrogen receptor-alpha levels in MCF-7 breast cancer cells predict cAMP and proliferation responses. Breast Cancer Res. 2005, 7: R101-112. 10.1186/bcr958.View ArticlePubMedGoogle Scholar
- Zivadinovic D, Watson CS: Membrane estrogen receptor-alpha levels predict estrogen-induced ERK1/2 activation in MCF-7 cells. Breast Cancer Res. 2005, 7: R130-144. 10.1186/bcr959.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/9/31/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.